Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling.

about

Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer.

P2860

Q51768067-A05C1DC6-0E57-4C7D-BC9E-A4552DE310FB

P2860

Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling.

Item

http://www.wikidata.org/entity/Q47141971

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cucurbitacin B and SCH772984 e ...... mTOR, STAT3 and ERK signaling.

@en

Cucurbitacin B and SCH772984 e ...... mTOR, STAT3 and ERK signaling.

@nl

type

Item

label

Cucurbitacin B and SCH772984 e ...... mTOR, STAT3 and ERK signaling.

@en

Cucurbitacin B and SCH772984 e ...... mTOR, STAT3 and ERK signaling.

@nl

prefLabel

Cucurbitacin B and SCH772984 e ...... mTOR, STAT3 and ERK signaling.

@en

Cucurbitacin B and SCH772984 e ...... mTOR, STAT3 and ERK signaling.

@nl

P1476

Cucurbitacin B and SCH772984 e ...... mTOR, STAT3 and ERK signaling.

@en

P2093

Jingkai Zhou

http://www.w3.org/2001/XMLSchema#string

Li-Mei Zhao

http://www.w3.org/2001/XMLSchema#string

Linfeng Ma

http://www.w3.org/2001/XMLSchema#string

Min Liang

http://www.w3.org/2001/XMLSchema#string

Tiangang Zhao

http://www.w3.org/2001/XMLSchema#string

Ying-Jie Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

Novel advances in pancreatic cancer treatment

Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia

In vitro and in vivo antitumor activity of a novel semisynthetic derivative of cucurbitacin B

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer

Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib

K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.

Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression

P304

103167-103181

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.21704

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29262554

http://www.w3.org/2001/XMLSchema#string

P932

5732720

http://www.w3.org/2001/XMLSchema#string

Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling.

about

P2860

P2860

Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932